SMS Messaging Added to Bracket RTSM Platform
Bracket SMS allows for reminders to be sent direct to patient mobile phones when they've opted in to the service.
Bracket announced that mobile patient reminders, delivered via SMS text messaging, are now available as a core component of Bracket's Randomization and Trial Supply Management (RTSM) 4.0 platform.
Bracket SMS allows for reminders to be sent direct to patient mobile phones when they've opted in to the service. Patient information is encrypted and stored safely, and both patients and investigators can opt out of the service at any time. SMS is available globally to any study utilizing Bracket RTSM.
Read the full release.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
